Company profile for Kling Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kling Biotherapeutics uses a proprietary platform to identify novel antibodies from patients to enable the generation of antibody and related biologic/cell therapies. Developer of antibody and antibody-derived drugs intended to treat cancer and infectious disease patients. The company's research utilizes a proprietary platform to identify novel antibodies from patients to enable the generation of antibodies and related biolog...
Kling Biotherapeutics uses a proprietary platform to identify novel antibodies from patients to enable the generation of antibody and related biologic/cell therapies. Developer of antibody and antibody-derived drugs intended to treat cancer and infectious disease patients. The company's research utilizes a proprietary platform to identify novel antibodies from patients to enable the generation of antibodies and related biological or cell therapies, helping medical personnel identify first-in-class druggable targets for human diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Meibergdreef 59 1105 BA Amsterdam
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

IPhEB Russia

Not Confirmed

envelop Contact Supplier

IPhEB Russia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/kling-biotherapeutics-to-present-key-applications-for-its-primary-b-cell-immortalization-screening-and-antibody-optimization-platform-technologies-at-pegs-europe-302291945.html

PR NEWSWIRE
31 Oct 2024

https://www.prnewswire.com/news-releases/kling-bio-announces-appointment-of-dr-stefano-gulla-as-chief-scientific-officer-302004984.html

PR NEWSWIRE
05 Dec 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty